ESR2 and non-small cell lung carcinoma: Given the synergistic effect of ESR2 in targeted therapy of NSCLC, the present study demonstrated that the combination of the ESR2 inhibitor TPHPP and osimertinib had a greater influence on tumour progression via in vivo and in vitro assays.